Uppsala Reports editor
@UMCGlobalSafety
Artificial intelligence is no longer on the horizon of drug safety—it's already here. From case processing to signal detection, AI is embedded throughout the pharmacovigilance cycle. Yet as generative AI models expand what's possible, they also raise critical questions: How do we harness their power responsibly? Where should we draw the line?
In this two-part episode of Drug Safety Matters, Niklas Norén, head of Research at Uppsala Monitoring Centre, explores how artificial intelligence can strengthen pharmacovigilance and where guardrails matter most.
Subscribe by visiting the Drug Safety Matters website.